Our Focus
Personalized Medicine
Personalized medicine represents a significant advance from most
current therapies, which were developed to detect and treat the
symptoms of disease broadly across all patients. Conventional drug
development approaches do not take into account that, due to genetic
variations, a disease may manifest itself slightly differently in
different types of patients. Fortunately, our technology offers the
ability to create a wide variety of medicines without incurring
additional expenses on research and development for each personalized
product.
Social Acceptance
Society is divided on the use of embryonic stem cells, even though
there is a general acceptance in terms of its use to treat numerous
conditions. Our technology uses adult stem cells, avoiding the ethical
concerns and clinical complications, such as immune response.
Additionally, our approach is superior to other adult stem cell
companies because our technology allows us to overcome the limitations
of adult stem cells. We can take cells from the bone marrow and make
them into neurons, so these cells are able to develop into tissues of
other germ layers, whereas other companies are unable to show strong
evidence of that potential.
Lowering Medical Costs
The cost of treating neurodegenerative disorders exceeds $100 billion
annually; the majority of costs are associated with patient care
rather than treatment of symptoms. The cost for prescription drugs was
over $5.5 billion in 2004 and is scheduled to double in approximately
5 years. The rising cost of newer treatments, coupled with the growing
number of elderly in this country, presents an expanding market for
technology that offers to cure such conditions. Our technology aims to
replace degenerative tissues with cells derived from modifying a
patients own bone marrow. The use of our therapy will translate to a
decreased dependence on conventional drug treatments and, substantial
savings in prescription costs and patient care, while providing an
improved quality of life for our clients.
|
